Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2012 02:58 ET | Source: ALK Abello

Aktietilbagekøb i ALK - uge 45

København, 2012-11-06 08:58 CET (GLOBE NEWSWIRE) -- Den 14. maj 2012 igangsatte ALK-Abelló A/S (“ALK”) et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 14/2012. Ved...
November 06, 2012 02:58 ET | Source: ALK Abello

Share Buy-Back in ALK - week 45

Copenhagen, 2012-11-06 08:58 CET (GLOBE NEWSWIRE) -- On 14 May 2012, ALK-Abelló A/S (“ALK”) initiated a share buy-back programme, cf. company announcement No. 14/2012. According to the...
October 30, 2012 03:48 ET | Source: ALK Abello

Share Buy-Back in ALK

Copenhagen, 2012-10-30 08:48 CET (GLOBE NEWSWIRE) -- On 14 May 2012, ALK-Abelló A/S (“ALK”) initiated a share buy-back programme, cf. company announcement No. 14/2012. According to the...
October 30, 2012 03:48 ET | Source: ALK Abello

Aktietilbagekøb i ALK - uge 44

København, 2012-10-30 08:48 CET (GLOBE NEWSWIRE) -- Den 14. maj 2012 igangsatte ALK-Abelló A/S (“ALK”) et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 14/2012. Ved...
October 29, 2012 11:13 ET | Source: ALK Abello

Release date of nine-month interim report (Q3) 2012 for ALK

Copenhagen, 2012-10-29 16:13 CET (GLOBE NEWSWIRE) -- On Monday 12 November 2012, ALK releases its interim report for the nine months ended 30 September 2012. ALK will hold a conference...
October 29, 2012 11:13 ET | Source: ALK Abello

Dato for offentliggørelse af delårsrapport for 9 måneder (Q3) 2012 for ALK

København, 2012-10-29 16:13 CET (GLOBE NEWSWIRE) -- Mandag, den 12. november 2012 offentliggør ALK delårsrapport for 9 måneder (Q3) 2012. ALK afholder samme dag kl. 14.00 (CET) en...
October 23, 2012 08:06 ET | Source: ALK Abello

Nordamerikansk fase III-studie med GRAZAX® afsluttet med succes. Indsendelse af registreringsansøgning til FDA forventes i 2013

København, 2012-10-23 14:06 CEST (GLOBE NEWSWIRE) -- Merck igangsatte studiet i 2011 for at vurdere effekten og sikkerheden af GRAZAX® vs. placebo i behandlingen af høfeber forårsaget af...
October 23, 2012 08:06 ET | Source: ALK Abello

North American Phase III trial with grass allergy immunotherapy tablet meets primary endpoint. FDA filing remains planned for 2013

Copenhagen, 2012-10-23 14:06 CEST (GLOBE NEWSWIRE) -- Merck initiated the trial in 2011 to evaluate the efficacy and safety of grass AIT versus placebo in the treatment of grass pollen...
October 23, 2012 03:14 ET | Source: ALK Abello

Aktietilbagekøb i ALK - uge 43

København, 2012-10-23 09:14 CEST (GLOBE NEWSWIRE) -- Den 14. maj 2012 igangsatte ALK-Abelló A/S (“ALK”) et aktietilbagekøbsprogram, jf. selskabsmeddelelse nr. 14/2012. Ved...
October 23, 2012 03:14 ET | Source: ALK Abello

Share Buy-Back in ALK - week 43

Copenhagen, 2012-10-23 09:14 CEST (GLOBE NEWSWIRE) -- On 14 May 2012, ALK-Abelló A/S (“ALK”) initiated a share buy-back programme, cf. company announcement No. 14/2012. According to the...